Towards modulating the gut microbiota to enhance the efficacy of immune-checkpoint inhibitors
Nature Reviews Clinical Oncology, Published online: 24 July 2023; doi:10.1038/s41571-023-00803-9Advances over the past decade have established a prominent role of the gut microbiota in the modulation of immune homeostasis and function, including in patients with cancer receiving immune-checkpoint inhibitors. In this Review, the authors summarize current knowledge of the role of the microbiota in this context, describe several methods of modulating the microbiota clinically to improve patient outcomes, and highlight important future directions in this expanding area of research. (Source: Nature Reviews Clinical Oncology)
Source: Nature Reviews Clinical Oncology - July 24, 2023 Category: Cancer & Oncology Authors: Rebecca C. Simpson Erin R. Shanahan Richard A. Scolyer Georgina V. Long Source Type: research
Immune-checkpoint inhibition for resectable non-small-cell lung cancer — opportunities and challenges
Nature Reviews Clinical Oncology, Published online: 24 July 2023; doi:10.1038/s41571-023-00794-7Several trials are testing immune-checkpoint inhibitors (ICIs), alone or in combination with chemotherapy, in patients with resectable non-small-cell lung cancer as an adjuvant, neoadjuvant or perioperative approach. However, the optimal use of ICIs with curative intent in patients with early stage non-small-cell lung cancer remains unclear. The authors of this Review discuss the current trial landscape and discuss challenges and opportunities. (Source: Nature Reviews Clinical Oncology)
Source: Nature Reviews Clinical Oncology - July 24, 2023 Category: Cancer & Oncology Authors: Giannis Mountzios Jordi Remon Lizza E. L. Hendriks Rosario Garc ía-Campelo Christian Rolfo Paul Van Schil Patrick M. Forde Benjamin Besse Vivek Subbiah Martin Reck Jean-Charles Soria Solange Peters Source Type: research
Platinum-ineligible: atezolizumab preferable
Nature Reviews Clinical Oncology, Published online: 21 July 2023; doi:10.1038/s41571-023-00806-6Platinum-ineligible: atezolizumab preferable (Source: Nature Reviews Clinical Oncology)
Source: Nature Reviews Clinical Oncology - July 21, 2023 Category: Cancer & Oncology Authors: David Killock Source Type: research
The global burden of lung cancer: current status and future trends
Nature Reviews Clinical Oncology, Published online: 21 July 2023; doi:10.1038/s41571-023-00798-3Lung cancer is the commonest cancer globally. Reflecting patterns of smoking and other risk factor exposures, both the incidence of and mortality from lung cancer are highest in economically developed countries. Nonetheless, developing and less economically developed countries are likely to have the biggest increases in lung cancer in the coming years. In this Review, the authors describe the global epidemiology of lung cancer, and how changes in exposures, socioeconomic status, public health interventions and better treatment s...
Source: Nature Reviews Clinical Oncology - July 21, 2023 Category: Cancer & Oncology Authors: Amanda Leiter Rajwanth R. Veluswamy Juan P. Wisnivesky Source Type: research
Quantitative PET-based biomarkers in lymphoma: getting ready for primetime
Nature Reviews Clinical Oncology, Published online: 17 July 2023; doi:10.1038/s41571-023-00799-2Despite advances in drug development for patients with lymphoma over the past decades, the identification of biomarkers for treatment selection remains an unmet need. The authors of this Review provide an overview of quantitative PET-based biomarkers in this patient population and discuss the challenges and opportunities in the integration of these biomarkers in clinical trials and the routine management of patients with lymphoma. (Source: Nature Reviews Clinical Oncology)
Source: Nature Reviews Clinical Oncology - July 17, 2023 Category: Cancer & Oncology Authors: Juan Pablo Alderuccio Russ A. Kuker Fei Yang Craig H. Moskowitz Source Type: research
A new era for glioma therapy — targeting mutant IDH
Nature Reviews Clinical Oncology, Published online: 17 July 2023; doi:10.1038/s41571-023-00804-8Hotspot point mutations in IDH1 occur in the vast majority of adult grade 2–3 gliomas. The understanding of their role in tumour biology continues to evolve. Therapeutic targeting of mutant IDH1 with vorasidenib demonstrated highly encouraging efficacy and minimal toxicity in a recent, randomized phase III trial involving patients with low-grade gliomas. (Source: Nature Reviews Clinical Oncology)
Source: Nature Reviews Clinical Oncology - July 17, 2023 Category: Cancer & Oncology Authors: David A. Reardon Daniel P. Cahill Source Type: research
Problematic crossovers in cancer drug trials
Nature Reviews Clinical Oncology, Published online: 17 July 2023; doi:10.1038/s41571-023-00805-7Crossover in a randomized trial can skew the interpretation of the efficacy of a cancer drug. In this Comment, I use examples from clinical trials presented at the 2023 ASCO annual meeting to highlight why ‘allowing’ crossover in randomized trials testing cancer drugs is problematic, and propose that crossovers should either be mandated or prohibited depending on the context. (Source: Nature Reviews Clinical Oncology)
Source: Nature Reviews Clinical Oncology - July 17, 2023 Category: Cancer & Oncology Authors: Bishal Gyawali Source Type: research
A critical appraisal of the ATLAS trial of maintenance therapy for multiple myeloma: end points, censoring and equipoise
Nature Reviews Clinical Oncology, Published online: 11 July 2023; doi:10.1038/s41571-023-00801-xA recent report from the ATLAS trial comparing different maintenance strategies following haematopoeitic stem cell transplantation for multiple myeloma provides an opportunity to explore various themes of critical appraisal, including end points, the equipoise of trial design, and the part censoring can play in the validity of results. (Source: Nature Reviews Clinical Oncology)
Source: Nature Reviews Clinical Oncology - July 11, 2023 Category: Cancer & Oncology Authors: Ghulam Rehman Mohyuddin Tomer Meirson Source Type: research
Safety of interrupting adjuvant endocrine therapy to conceive: early data are POSITIVE
Nature Reviews Clinical Oncology, Published online: 06 July 2023; doi:10.1038/s41571-023-00797-4Planning for a pregnancy in patients receiving adjuvant endocrine therapy following a diagnosis of hormone receptor (HR)-positive early stage breast cancer is challenging. Recent data from the POSITIVE trial provide reassuring prospective evidence that a temporary interruption of endocrine therapy for women with HR-positive breast cancer who are trying to conceive can be considered safe in the short term for selected patients. (Source: Nature Reviews Clinical Oncology)
Source: Nature Reviews Clinical Oncology - July 6, 2023 Category: Cancer & Oncology Authors: Luca Arecco Matteo Lambertini Source Type: research
New anti-angiogenic option for mCRC
Nature Reviews Clinical Oncology, Published online: 29 June 2023; doi:10.1038/s41571-023-00800-yNew anti-angiogenic option for mCRC (Source: Nature Reviews Clinical Oncology)
Source: Nature Reviews Clinical Oncology - June 29, 2023 Category: Cancer & Oncology Authors: David Killock Source Type: research
Gut OncoMicrobiome Signatures (GOMS) as next-generation biomarkers for cancer immunotherapy
Nature Reviews Clinical Oncology, Published online: 26 June 2023; doi:10.1038/s41571-023-00785-8Many studies attempting to identify biomarkers for predicting of immune-checkpoint inhibitor (ICI) efficacy have led to the description of Gut OncoMicrobiome Signatures (GOMS). Several GOMS support an association between oncogenesis and intestinal dysbiosis, and other GOMS are shared between patients with several cancer subtypes and individuals with seemingly unrelated chronic inflammatory disorders. The authors of this Review discuss these patterns as well as the findings from a meta-analysis of GOMS associated with clinical be...
Source: Nature Reviews Clinical Oncology - June 26, 2023 Category: Cancer & Oncology Authors: Andrew Maltez Thomas Marine Fidelle Bertrand Routy Guido Kroemer Jennifer A. Wargo Nicola Segata Laurence Zitvogel Source Type: research
Telemedicine as patient-centred oncology care: will we embrace or resist disruption?
Nature Reviews Clinical Oncology, Published online: 26 June 2023; doi:10.1038/s41571-023-00796-5Telemedicine represents the practical embodiment of patient-centred oncology care, a concept that has become increasingly popular in the past few years. Yet despite the demonstrated benefits of telemedicine, its longitudinal adoption remains limited. Herein we discuss some of the potential challenges that telemedicine faces, as we underutilize this approach relative to its anticipated value. (Source: Nature Reviews Clinical Oncology)
Source: Nature Reviews Clinical Oncology - June 26, 2023 Category: Cancer & Oncology Authors: Howard Jack West Erin Bange Fumiko Chino Source Type: research
A triple dose of optimism: an initial foray into triplet therapy in metastatic renal cell carcinoma
Nature Reviews Clinical Oncology, Published online: 23 June 2023; doi:10.1038/s41571-023-00795-6COSMIC-313 combines all of the approved drugs against actionable targets in renal cell carcinoma into one triplet regimen. Although this approach has greater clinical efficacy than one of the standard-of-care doublet therapies, toxicities can limit adequate drug administration and, thus, we argue that this regimen should not yet be adopted. We also discuss ongoing investigations of other triplet regimens. (Source: Nature Reviews Clinical Oncology)
Source: Nature Reviews Clinical Oncology - June 23, 2023 Category: Cancer & Oncology Authors: Kathryn E. Beckermann Brian I. Rini Source Type: research
Antigen presentation in cancer — mechanisms and clinical implications for immunotherapy
Nature Reviews Clinical Oncology, Published online: 16 June 2023; doi:10.1038/s41571-023-00789-4Immune-checkpoint inhibitors (ICIs) and other immunotherapies have revolutionized the treatment of patients with cancer. Nonetheless, most patients do not derive durable benefit, indicating a need for biomarkers to guide treatment selection. In this Review, the authors describe the role of antigen presentation in response to ICIs and other immunotherapies, with a focus on the role of molecular and/or genomic alterations affecting antigen presentation. (Source: Nature Reviews Clinical Oncology)
Source: Nature Reviews Clinical Oncology - June 16, 2023 Category: Cancer & Oncology Authors: Kailin Yang Ahmed Halima Timothy A. Chan Source Type: research
From ASCO 2023
Nature Reviews Clinical Oncology, Published online: 14 June 2023; doi:10.1038/s41571-023-00792-9From ASCO 2023 (Source: Nature Reviews Clinical Oncology)
Source: Nature Reviews Clinical Oncology - June 14, 2023 Category: Cancer & Oncology Authors: Diana Romero Source Type: research
